Axial spondyloarthritis
ImmunologyΒ· 4 reviewed drugsΒ· 8607 cited findings behind them
What the regulatory reviews cover
Regulatory review documents in this library for axial spondyloarthritis include Cosentyx and Erelzi. Cosentyx is indicated for active ankylosing spondylitis (AS) and active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Erelzi is indicated for Ankylosing Spondylitis (AS).
Different drugs were studied in different trials, so figures are not head-to-head. For Cosentyx, a PASI 75 response of 95 was reported. For Erelzi, the PK similarity (90% CIs for ratios of geometric mean of AUC0-inf, AUC0-Οlast, and Cmax) was within 80% to 125%.
The drugs β one cited result each
| Cosentyx Novartis AG | PASI 75 response: 95 NOVARTIS PHARMS CORP β Cosentyx FDA Review (NDA/BLA 125504,, p.26 |
| Humira AbbVie Inc. | 3502 cited findings on the drug page β |
| Cimzia UCB SA | 917 cited findings on the drug page β |
| Erelzi Novartis AG | PK similarity (90% CIs for ratios of geometric mean of AUC0-inf, AUC0-Οlast, and Cmax): within 80% to 125% SANDOZ β Erelzi FDA Summary Review (NDA/BLA 761042, 2016), p.9 |
Different drugs were studied in different trials β these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs β searchable, comparable and answerable in plain language β is in the Immunology research library β
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only β not medical or investment advice.